PE
PTCT icon

Point72 Europe’s PTC Therapeutics PTCT Stock Holding History

Point72 Europe’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$3.83M Buy
+62,407
New +$3.25M 0.19% 99

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Europe's PTCT Position: Q3 2025 in Review

Point72 Europe opened a new position in PTC Therapeutics (PTCT) in Q3 2025: 62,407 shares worth $3.83M. The stake represents 0.19% of the portfolio and ranks #99 among its holdings.

293 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

  • Point72 Europe held 62,407 shares of PTC Therapeutics worth $3.83M as of Q3 2025.
  • PTC Therapeutics was a new Point72 Europe position in Q3 2025.
  • PTC Therapeutics made up 0.19% of Point72 Europe's portfolio in Q3 2025, its #99 holding.
  • 293 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.